Request Demo

Last update 11 Sep 2026

Biotin

Last update 11 Sep 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryBiotin, also known as vitamin B7 or vitamin H, is one of the B vitamins. It is essential for the metabolism of carbohydrates, fats, and proteins. Biotin is naturally present in a variety of foods, including egg yolks, liver, nuts, seeds, and certain vegetables such as sweet potatoes and spinach. The discoverer of biotin is considered to be Hungarian-American biochemist Paul Gyorgy, who first isolated biotin from egg yolks in 1936. Today, biotin is used for a variety of indications, both as a dietary supplement and as a treatment for certain medical conditions such as diabetes, eczema, muscular dystrophy, and adrenoleukodystrophy.

Drug Type

Small molecule drug

Synonyms

(+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid, (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valeric acid, 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid

+ [21]

Target

ABCD1

Action

inhibitors

Mechanism

ABCD1 inhibitors(ATP Binding Cassette Subfamily D Member 1 inhibitors)

Therapeutic Areas

Endocrinology and Metabolic DiseaseSkin and Musculoskeletal DiseasesNervous System Diseases+ [2]

Active Indication

Biotin DeficiencyDiabetes MellitusEczema+ [3]

Inactive Indication

Amyotrophic Lateral SclerosisCharcot-Marie-Tooth Disease, Type IaCharcot-Marie-Tooth Disease, Type Ib+ [6]

Originator Organization-

Active Organization

Harvard Medical SchoolCiberer

Washington & Jefferson College

+ [2]

Inactive Organization

MedDay Pharmaceuticals SA

License Organization-

Drug Highest PhaseApproved

First Approval Date

South Korea (12 Dec 2016),

Biotin Deficiency

RegulationOrphan Drug (United States)

Structure/Sequence

Molecular FormulaC10H16N2O3S

InChIKeyYBJHBAHKTGYVGT-ZKWXMUAHSA-N

CAS Registry58-85-5

Clinical Trials associated with Biotin

CTR20262148

/ CompletedNot Applicable

生物素片在中国健康试验参与者中随机、开放、单剂量、两制剂、两周期、两序列、自身交叉的空腹和餐后状态下生物等效性预试验

[Translation] A preliminary bioequivalence study of biotin tablets in Chinese healthy participants under randomized, open-label, single-dose, two-formulation, two-period, two-sequence, self-crossover fasting and postprandial conditions.

以北京斯利安药业有限公司生产的生物素片（规格：10mg）为受试制剂，Strathmann GmbH & Co. KG生产、北京斯利安药业有限公司提供的生物素片（规格：10mg，商品名：Gabunat®）为参比制剂，在空腹和餐后状态下初步评价受试制剂同参比制剂的生物等效性，为正式试验提供设计依据。

[Translation]

Using biotin tablets (10mg) manufactured by Beijing Silian Pharmaceutical Co., Ltd. as the test formulation and biotin tablets (10mg, trade name: Gabunat®) manufactured by Strathmann GmbH & Co. KG and provided by Beijing Silian Pharmaceutical Co., Ltd. as the reference formulation, the bioequivalence of the test formulation and the reference formulation was initially evaluated under fasting and postprandial conditions, providing a design basis for the formal trial.

Start Date25 May 2026

Sponsor / Collaborator

Beijing Silian Pharmaceutical Co., Ltd.

NCT07302880

/ RecruitingNot ApplicableIIT

The Acute Interference of Biotin in Blood Analysis

Biotin, also known as vitamin B7, is a water-soluble vitamin. It is essential for several metabolic processes in the body, including glucose, lipid, and protein metabolism, as it acts as a coenzyme in several carboxylation reactions. Biotin, available as an over the counter supplement, is widely used to improve nail and hair growth. The use of biotin supplements can interfere with various laboratory tests, due to the use of the streptavidin-biotin interaction in several immunoassays. The investigators therefore wish to assess the acute impact of biotin supplementation on various laboratory assays, with focus on the immediate post-ingestion effects and the time frame in which biotin interference is most pronounced.

Start Date17 Mar 2026

Sponsor / Collaborator

University of Copenhagen

[+1]

ISRCTN44141067

/ Active, not recruitingNot Applicable

A randomized, double-blind, placebo-controlled study evaluating the effects of a polyphenol-rich red and black currant extract combined with biotin on wrinkle morphology, skin surface roughness, and hair shedding

Start Date15 Sep 2025

Sponsor / Collaborator-

100 Clinical Results associated with Biotin

100 Translational Medicine associated with Biotin

100 Patents (Medical) associated with Biotin

18,983

Literatures (Medical) associated with Biotin

31 Dec 2026·Gut Microbes

Genome-scale metabolic models predict diet- and lifestyle-driven shifts of ecological interactions in the gut microbiome

Article

Author: Kaleta, Christoph ; Poyet, Mathilde ; Groussin, Mathieu ; Franke, Andre ; Waschina, Silvio ; Lieb, Wolfgang ; Moors, Karlis Arturs ; Rühlemann, Malte ; Kadibalban, A. Samer ; Laudes, Matthias ; Schlicht, Kristina ; Marinos, Georgios

Microbiomes and their host environments form complex, interconnected ecosystems. The microbial species within a microbiome, on the one hand, compete for resources, while on the other hand, they exchange vital metabolites to support their survival. These interactions are influenced by the microbial genetic repertoire, environmental conditions, and availability of nutrients. We developed EcoGS (http://www.github.com/KaletaLab/EcoGS), a metabolic modeling tool designed to predict the ecological interactions between pairs of microbes. Applying EcoGS to the microbiomes of two distinct human cohorts revealed a shift from collaborative to exploitative ecological interactions associated with increased dietary intake of simple sugars (glucose and fructose) in diabetic individuals and those living industrialized lifestyles. On the other hand, the consumption of cobalamin (vitamin B12), phylloquinone (vitamin K1), and biotin (vitamin B7), among other compounds, was associated with increased collaboration in the gut microbiome. We conclude that the abundance of simple sugars as an energy source reduces the necessity for microbes to cooperate, thereby increasing competition and hostility among microbiome members. Moreover, our study proposes multiple compounds, such as urate, deoxyadenosine, deoxyguanosine, and hypoxanthine, for in vitro validation tests as dietary interventions that have the potential to restore the ecological balance within the community. EcoGS serves as a valuable tool for exploring microbiome dynamics and their connections to environmental changes and disease.

01 Sep 2026·FOOD RESEARCH INTERNATIONAL

Metabolomics combined with machine learning reveals candidate metabolites and a putative working network associated with cereulide production in emetic Bacillus cereus

Article

Author: Qin, Keyuan ; Wu, Qingping ; Chen, Minling ; Wang, Juan ; Feng, Ying ; Li, Jiaxun ; Shang, Yuting ; Chen, Moutong ; Ding, Yu

Cereulide, a heat-stable toxin produced by Bacillus cereus, is recognized as a major foodborne risk. However, the metabolic features associated with cereulide production and their biological relevance remain insufficiently characterized. This study aimed to prioritize candidate metabolites associated with cereulide-related phenotypes and to explore their potential pathway-level relationships. An integrated analytical pipeline combining RF-CNN-assisted feature prioritization, pathway enrichment, time-series profiling, and temporal association analysis was developed to support both classification performance and biological interpretability. Using fivefold cross-validation, nine candidate metabolites were prioritized. Based on pathway enrichment and temporal analyses across three growth stages, histidinol, L-leucine, and biotin were highlighted as candidate metabolites associated with cereulide-related phenotypes. A putative working network describing their potential relationships was then proposed. In exogenous supplementation experiments, L-leucine and biotin were associated with reduced cereulide production, whereas histidine showed the opposite trend, providing phenotypic support for the biological relevance of the related pathways under the tested conditions. Overall, this study establishes a metabolomics-guided strategy for prioritizing candidate metabolites and provides biologically interpretable and testable hypotheses for exploring the potential metabolic basis of B. cereus-associated phenotypes.

22 Jul 2026·JCI Insight

A Slc5a6-deficient mouse model reveals metabolically driven cardiomyopathy with therapeutic potential for vitamin-based intervention

Article

Author: Roland, Dominique ; Phillips, Lauren C. ; Richardson, Gavin D. ; Redgrave, Rachael E. ; Burn, John ; Kerridge, Scott T. ; Morgan, Andrew D.H. ; Phillips, Helen M. ; Haufroid, Vincent ; Fullerton, Millie O. ; Crossley, Rebecca ; Bamforth, Simon D. ; Spray, Luke ; Mercier, Nathalie ; Merces, George ; Dewulf, Joseph P.

The sodium-dependent multivitamin transporter, encoded by SLC5A6 , mediates cellular uptake of biotin and pantothenic acid, essential cofactors for energy metabolism. We identified 2 families with SLC5A6 mutations presenting with early-onset dilated cardiomyopathy (DCM). To investigate the link between vitamin deficiency and cardiomyopathy, we generated a cardiac-specific SLC5A6 -knockout ( Slc5a6 cKO ) mouse model and evaluated the impact of vitamin supplementation. Slc5a6 cKO mice developed progressive cardiac dysfunction, culminating in cardiac pathology and premature death at 26 weeks; earlier stages exhibited cardiomyocyte hypertrophy, fibrosis, impaired coenzyme A synthesis, and metabolic imbalance, indicating progression toward cardiomyopathy. Cardiac magnetic resonance imaging and ECG confirmed progressive functional decline. Proteomic analysis revealed early mitochondrial metabolic disruption and extracellular matrix protein upregulation at 8 weeks, preceding overt cardiac dysfunction. Strikingly, vitamin supplementation from preconception onwards prevented the cardiac phenotype, preserving cardiac structure, function, morphology and survival. This paralleled the clinical outcome in one patient who received early vitamin treatment, compared with another who required a heart transplant without vitamin treatment. This study establishes a direct link between SLC5A6 -mediated vitamin transport, mitochondrial function, and cardiac health. It highlights how vitamin deficiency contributes to cardiomyopathy pathogenesis and supports early vitamin supplementation as a potential therapeutic strategy for metabolic cardiomyopathies.

News (Medical) associated with Biotin

05 Sep 2026

·www.prnewswire.com

Best Hair Growth Products for Men (2026): Happy Head Personalized Formulas Reviewed by Consumer365

NEW YORK, Sept. 5, 2026 /PRNewswire/ -- Consumer365 has reviewed Happy Head for its personalized approach to prescription hair-growth treatment, highlighting a selection of dermatologist-guided formulas designed for men managing thinning hair and male pattern hair loss. Best Hair Growth Products for Men Happy Head - a telehealth provider of personalized, dermatologist-prescribed hair-loss treatments Hair loss treatment has become increasingly personalized as prescription medicine moves into telehealth. Instead of relying on a single standardized formula, Happy Head connects customers with board-certified dermatologists who review medical history, allergies, hair-loss patterns and treatment goals before prescribing a personalized regimen. Treatments are then compounded and shipped directly to the customer. The approach is particularly relevant for consumers researching the best hair growth products for men, a category that includes topical treatments, oral medications and combination regimens. Happy Head offers each format through a telehealth model that does not require an in-person doctor visit. Happy Head offers personalized compounded formulas including dutasteride, finasteride, minoxidil to help you achieve your personal hair growth goals. Consumer365 Recognizes Happy Head's Personalized Treatment Model Consumer365 has recognized Happy Head for combining prescription hair-growth medicine with dermatologist oversight and personalized formulations. Happy Head states that all consultations are conducted by board-certified doctors. The platform also provides ongoing dermatologist support, allowing treatment formulas to be adjusted when medically appropriate. The company's formulations use FDA-approved active pharmaceutical ingredients, although compounded prescription formulations themselves are not FDA-approved. Happy Head's website identifies ingredients such as finasteride and minoxidil among its prescription options. The distinction is important for consumers evaluating prescription hair-loss care. The active ingredients may have established clinical uses, while compounded combinations require individualized medical oversight and are not equivalent to an FDA-approved finished drug product. Happy Head says most customers begin seeing progress within three to six months of consistent daily use. Early changes may include reduced shedding or the appearance of fine new hairs. Individual responses and timelines can vary. TopicalRx SuperSolutionTM ProBlend Topical Rx SuperSolution TM ProBlend is designed for consumers seeking a multi-ingredient topical prescription formula. The formulation includes up to 8% minoxidil alongside ingredients such as dutasteride, finasteride, cetirizine HCl, latanoprost, melatonin, caffeine, tretinoin, vitamin D3 and biotin. The formula is intended to address multiple aspects of hair and scalp health through a single topical treatment. Minoxidil is used to support hair growth, while dutasteride and finasteride target DHT, a hormone associated with male pattern hair loss. Tretinoin is included in the formulation to support minoxidil absorption. Happy Head describes its topical formulations as freshly compounded prescriptions rather than mass-produced products. Formula adjustments are available based on a customer's medical needs and dermatologist assessment. A higher concentration of an active ingredient does not automatically make a treatment appropriate for every person. Prescription-strength formulations require evaluation by a qualified healthcare provider. TopicalRx Solution + SuperCapsuleTM: Dutasteride & MinoxidilRx For men interested in combining topical and oral treatment, Happy Head offers Topical Rx Solution + SuperCapsule TM. The topical solution can contain 0.3% dutasteride, up to 8% minoxidil, retinoic acid and hydrocortisone. The accompanying SuperCapsule contains 0.5 mg dutasteride, 1.25 mg minoxidil and 2,000 IU of vitamin D3. The two-part regimen uses different delivery methods. The topical formula is applied directly to the scalp, for a total of 2.0ml daily, while the capsule provides oral medication once daily. Dutasteride and minoxidil are prescription medications that can carry risks and potential side effects, making medical screening an important part of the process. Happy Head's telehealth assessment is designed to determine whether a prescription treatment is appropriate. Medical history, allergies and the degree of hair loss are among the factors considered during the consultation. SuperCapsuleTM + ED Performance SuperCapsule TM + ED Performance takes a different approach by combining hair-loss treatment with medication for erectile dysfunction in a once-daily capsule. The formulation contains dutasteride, tadalafil and vitamin D3. Dutasteride is used in hair-loss treatment, while tadalafil is a prescription medication used for erectile dysfunction. Happy Head developed the combination for men seeking an oral hair-growth option alongside treatment for sexual performance concerns. The combination also underscores the importance of medical screening. Tadalafil can interact with certain medications and may not be appropriate for people with particular cardiovascular conditions. A dermatologist or other qualified healthcare professional can assess whether the treatment is suitable. The product provides an alternative to a topical routine for men who prefer oral medication. As with other prescription hair-growth treatments, outcomes can vary and consistent use is necessary for evaluating progress. What Sets the Happy Head Model Apart Happy Head's approach centers on prescription treatment supported by telehealth rather than a one-size-fits-all regimen. Customers complete an online assessment before connecting with a board-certified dermatologist. Once a prescription is approved, the treatment is prepared and shipped directly to the customer. Happy Head reports that more than 1 million prescriptions have been delivered through its platform. The company also says its treatments are shipped monthly in discreet packaging, with refills automatically sent as part of eligible subscriptions. Pricing varies according to the formulation and ingredients. Happy Head currently lists custom compounded prescription formulas ranging from $59 to $119 per month. Promotional savings and subscription terms can change over time. For consumers comparing the best hair growth products for men, the key consideration is not simply the number of ingredients or strength of a formula. Hair loss can have different causes, and prescription medications have different safety considerations. A dermatologist-guided assessment can help determine whether topical medication, oral treatment or a combination approach is appropriate. Consumer365's recognition of Happy Head highlights the growing role of personalized telehealth in hair-loss care. With multiple prescription formats and dermatologist oversight, the platform gives men a range of treatment pathways while keeping medical evaluation central to the process. The full review is available at the Consumer365 website. Happy Head offers personalized compounded prescription treatments. Compounded medications are not FDA-approved, and some ingredients or uses discussed may be prescribed off-label. Treatment suitability and results vary. A licensed healthcare provider must determine whether a treatment is appropriate. Review Happy Head's Drug Safety & Information. About Happy Head Happy Head is the industry-leading, dermatologist-founded telehealth company redefining the future of precision hair care. Founded in 2021 by renowned dermatologists and hair loss experts, Dr. Ben Behnam and Dr. Sean Behnam, the company combines clinical expertise with breakthrough science to deliver personalized solutions for hair preservation and restoration. From custom-compound topicals to its innovative StrandIQ™ DNA Starter Kit, Happy Head empowers individuals to make informed decisions to take control of their hair health journey from the privacy of their home, with recommendations that are clinically proven and tailored to individual needs. The mission is simple: help people regrow their hair and restore their confidence with personalized, medical-grade treatments that actually work. Learn more at . About Consumer365.org: Consumer365 provides consumer news and industry insights. As an affiliate, Consumer365 may earn commissions from sales generated using links provided. SOURCE Consumer365.org 21% more press release views with Request a Demo

Drug Approval

19 May 2026

·retinalphysician.com

Bausch + Lomb Launches New Vitamin Formulation

Bausch + Lomb has announced the launch of PreserVision AREDS3 eye vitamins, a new formulation that combines the clinically proven AREDS2 nutrients recommended by the National Eye Institute with a proprietary B-vitamin complex intended to support macular health across a broader range of patients with age-related macular degeneration (AMD). The product includes thiamin, riboflavin, niacin, pantothenic acid, vitamin B6, biotin, folate, and vitamin B12. Bausch + Lomb said the supplement is intended to provide support through antioxidant protection, cellular nutritional support, and improved nutrient absorption. Recent research has examined potential associations between B-vitamin supplementation and AMD risk. A narrative review published in Ophthalmology and Therapy summarized findings from more than 20 human studies involving nearly 30,000 individuals. Among the cited studies was the Women’s Antioxidant and Folic Acid Cardiovascular Study, which reported an association between certain B-vitamin supplementation regimens and reduced AMD risk. In a press release, Bausch + Lomb said that it is planning a long-term clinical trial to evaluate the PreserVision AREDS3 supplement. RP

07 May 2026

·www.sciencedaily.com

Doctors warn this popular vitamin may quietly disrupt cancer care

Many cancer patients turn to biotin supplements hoping to restore hair lost during treatment, but experts warn the popular vitamin may do more harm than good. While biotin is often marketed for stronger hair and nails, there’s little evidence it actually helps cancer-related hair loss—and it can dangerously interfere with lab tests. Doctors say the supplement can distort key blood markers, potentially masking cancer recurrence or delaying treatment decisions.Hair loss is one of the most upsetting side effects of cancer treatment, and many patients look for ways to bring their hair back. One option that has gained popularity is biotin, a vitamin commonly promoted for stronger hair and nails. But experts say the benefits are uncertain, and the risks may be overlooked. There is little scientific evidence that oral biotin helps hair or nail growth in people undergoing or recovering from cancer treatment. More concerning, it may interfere with medical testing, according to Brittany Dulmage, MD, an oncodermatologist at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Biotin, also known as vitamin B7, helps the body produce proteins such as keratin, which supports hair, skin and nails. However, true biotin deficiency is uncommon because the vitamin is widely found in foods like fruits, vegetables, meats, eggs and dairy products. "People have the misconception that biotin supplements are harmless and there's no reason not to take them. The reality is that the supplements may cause inaccurate lab results, resulting in a delay or change in patients' treatment plans," she said. Dulmage also serves as associate director of dermatology at The Ohio State University College of Medicine and leads the Oncodermatology Clinic, where patients receive care for hair, skin and nail side effects caused by treatments such as chemotherapy, immunotherapy or targeted therapy. "More than half the patients who come to see me with a problem related to hair loss are on a supplement that they've started on their own after learning about it online, by word of mouth and sometimes even at the advice of their doctor," she said. To highlight these concerns, Dulmage authored a paper in JCO Oncology Practice urging oncologists to discuss hair loss openly with patients and explain how biotin could affect test results. How Biotin Can Distort Cancer Lab Results Biotin can interfere with certain blood tests used to monitor cancers, including prostate, thyroid, ovarian and breast cancers. Some of these tests rely on chemical reactions that involve biotin, so taking supplements can cause results to appear higher or lower than they truly are. "Biotin does not actually change the levels of hormones in the body, but it interferes with the way those levels could be checked when blood work is done," she said. "For some of the hormones such as prostate specific antigen, PSA, or thyroid stimulating hormone, TSH, it may falsely suppress or lower those levels, potentially masking cancer recurrence in cancer survivors. For reproductive hormones including estrogen and testosterone, it may falsely elevate levels, resulting in delayed therapy." A Patient's Experience With Biotin and Lab Results Anna Malagoli of Columbus, like many cancer patients, worried about losing her hair during breast cancer treatment. "Your hair is very much a part of you. One of the first things you ask is 'Am I going to lose my hair?' It's such an important thing for people -- not everybody looks good with no hair," she said. After her cancer went into remission, she wanted to restore her long curly hair and began taking biotin supplements after reading about them online. "The amount of information on the Internet can lead you in different directions. I was taking so much biotin it's not even funny," she said. "Nobody mentioned one word that biotin vitamins or minerals or supplements could interfere with your treatment or your testing." Inconsistent Test Results Raise Concerns Malagoli only became aware of the issue during a visit with Dulmage. Looking back, she said the explanation fit her experience. "My lab results were inconsistent. They just didn't balance out with what I was feeling so that was a red flag. I think it had to do with the supplements I was taking," she said. For patients who choose to keep using biotin, Dulmage advises stopping it at least 72 hours before scheduled blood tests. "The challenge is that not all blood work is planned so you may not be able to hold your biotin. Biotin can also impact the levels of troponin, which is a marker of whether or not someone is having a heart attack," she said. "Obviously, you're not planning to have a heart attack so you can't hold biotin before troponin levels are checked. This is why I recommend to patients -- think about not taking it at all, especially since very few people are biotin deficient." Safer Options for Hair Loss During Cancer Treatment Instead of biotin, Dulmage suggests using minoxidil to address hair loss. This treatment is FDA approved, widely available over the counter, and comes in topical forms such as lotions and foams. It is considered safe and effective for most people, though it is not recommended during pregnancy or breastfeeding. "If you have been trying minoxidil for several months and not seeing any improvement or want to know about other options, see a dermatologist. There are many other types of treatments that may be an option," she said. Malagoli has tried both approaches and found that minoxidil worked better for her. "I don't know if my body just doesn't assimilate the supplements as well, but minoxidil is definitely more effective long-term," she said. "I would say it's super important to listen to your doctors and not just do your thing."

100 Deals associated with Biotin

External Link

KEGG	Wiki	ATC	Drug Bank
D00029	Biotin	A11HA05	DB00121

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Biotin Deficiency	South Korea	Chodang Pharm Co., Ltd.	12 Dec 2016
Diabetes Mellitus	-	-	-
Eczema	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Sclerosis	NDA/BLA	European Union	MedDay Pharmaceuticals SA	-
Adrenoleukodystrophy	Phase 3	France	MedDay Pharmaceuticals SA	01 Oct 2014
Adrenoleukodystrophy	Phase 3	Germany	MedDay Pharmaceuticals SA	01 Oct 2014
Adrenoleukodystrophy	Phase 3	Spain	MedDay Pharmaceuticals SA	01 Oct 2014
Multiple Sclerosis, Chronic Progressive	Phase 3	France	MedDay Pharmaceuticals SA	01 Oct 2013
Optic Neuritis	Phase 3	France	MedDay Pharmaceuticals SA	01 Oct 2013
Optic Neuritis	Phase 3	United Kingdom	MedDay Pharmaceuticals SA	01 Oct 2013
Vision, Low	Phase 3	France	MedDay Pharmaceuticals SA	01 Oct 2013
Vision, Low	Phase 3	United Kingdom	MedDay Pharmaceuticals SA	01 Oct 2013
Charcot-Marie-Tooth Disease, Type Ia	Phase 2	France	MedDay Pharmaceuticals SA	05 Dec 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EADV2023	Not Applicable	-	61	Oral biotin	nagdjdlxxw(uaawxmwwiy) = ceythlosmx pdfdavwhcx (gzmauztzbb ) View more	Positive	11 Oct 2023
				Pyridoxine	nagdjdlxxw(uaawxmwwiy) = lzsscfzuoy pdfdavwhcx (gzmauztzbb ) View more
NCT02936037 (SPI2, Pubmed) Manual	Phase 3	Multiple Sclerosis, Chronic Progressive	642	MD1003	wnokxydtlu(czhairmkfv) = dbnhkovqek hsxarpcjch (gydpdrdhsx ) View more	Negative	01 Dec 2020
				Placebo	wnokxydtlu(czhairmkfv) = lrwemvlodi hsxarpcjch (gydpdrdhsx ) View more
NCT02936037 (SPI2, CTgov)	Phase 3	Multiple Sclerosis, Chronic Progressive	642	PLACEBO (GROUP 1)	ddwsisdbig(traaficpge) = ycwlntlbzm tijbwoiked (zcgybtnnsj, tuugttohwl - bbsrapvmoe) View more	-	23 Nov 2020
				MD1003 100mg capsule (GROUP 2)	ddwsisdbig(traaficpge) = ozyjvjjtaw tijbwoiked (zcgybtnnsj, uwsmdjeakh - pzwlevtqvu) View more
NCT04223232 (CTgov)	Phase 1	-	6	[14C]-MD1003	osxcmbmeql(lnzeblecwc) = pcaqskjdcn mknbujizpa (irvyobgecl, 16.9) View more	-	02 Nov 2020
NCT02967679 (phase 2b open label, uncontrolled, pilot study, CTgov)	Phase 2	Charcot-Marie-Tooth Disease, Type Ia \| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating \| Central Nervous System Diseases ... View more	15	MD1003	bcqstqsgpf(ydcifdptif) = qgpvegmafu xxxquooaru (faajogrjjb, 11.45) View more	-	02 Nov 2020
NCT02220933 (MS-SPI, ECTRIMS2019)	Phase 3	Multiple Sclerosis	133	MD1003	pffjskudkr(uzohtuovza) = The main reasons for treatment withdrawal (M12 to M60) were: perceived lack of efficacy (34 patients), consent withdrawal (23 patients), and discontinuations due to AEs (8 patients) yrktgegwyf (gbjrjecurp ) View more	Positive	10 Sep 2019
ECTRIMS2019	Not Applicable	Multiple Sclerosis	579	MD1003 high dose pharmaceutical-grade biotin	ilinqjobxr(nzgtaeefem) = hvveogeqby uiplxcioya (elulgkqvms )	Positive	10 Sep 2019
				Concomitant immunotherapy	ilinqjobxr(nzgtaeefem) = ulpggsqduf uiplxcioya (elulgkqvms )
NCT02220933 (MS-SPI, AAN2019)	Phase 3	Multiple Sclerosis, Chronic Progressive	154	MD1003	kvzqhkcyob(ogoohpagge) = teyeeqokgf bodpjadcok (lldmrxqcmn ) View more	Positive	09 Apr 2019
				Placebo	kvzqhkcyob(ogoohpagge) = zjoitfszfc bodpjadcok (lldmrxqcmn ) View more
NCT02936037 (SPI2, ECTRIMS2018)	Phase 3	Multiple Sclerosis	660	MD1003 300 mg/day	xnhasdenxd(dkdequbffk) = xuuzguwqbo cfbvbcuycc (umgbyfrlgs )	-	09 Oct 2018
				Placebo	xnhasdenxd(dkdequbffk) = bvqbjvjseh cfbvbcuycc (umgbyfrlgs )
NCT02220933 (MS-SPI, ECTRIMS2018)	Phase 3	Multiple Sclerosis	154	MD1003	mcifuziscx(zcsypbqbzy) = A total of 38% vs 34% of pts in MM and PM groups, respectively, experienced AEs ojizkhfuam (torycfbdpz )	Positive	09 Oct 2018
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis